(Q40509774)

21 September 2017

title

Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium (English)

1 reference

transitional cell carcinoma

21 September 2017

main subject

1 reference

1 reference

1 reference

1

John D Hainsworth

1 reference

21 September 2017

Anthony A Meluch

2

1 reference

21 September 2017

Sharlene Litchy

3

1 reference

21 September 2017

Frederick M Schnell

4

1 reference

21 September 2017

James D Bearden

5

1 reference

21 September 2017

Kathleen Yost

6

1 reference

21 September 2017

F Anthony Greco

7

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

21 September 2017

1 reference

21 September 2017

volume

103

1 reference

21 September 2017

issue

11

1 reference

21 September 2017

page(s)

2298-2303

1 reference

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21078

7 January 2021

Identifiers

DOI

10.1002/CNCR.21078

1 reference

21 September 2017

1 reference